Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#101 / 200 Total
RCON - Recon Technology Ltd - Stock Price Chart
TickerRCON [NASD]
CompanyRecon Technology Ltd
CountryChina
IndustryOil & Gas Equipment & Services
Market Cap70.72MEPS (ttm)-0.25
P/E-EPS this Y29.17%
Forward P/E-EPS next Y76.47%
PEG-EPS past 5Y38.93%
P/S7.34EPS next 5Y-
P/B1.34EPS Q/Q-
Dividend-Sales Q/Q-0.22%
Insider Own1.86%Inst Own11.14%
Insider Trans0.00%Inst Trans-0.67%
Short Float0.02%Earnings-
Analyst Recom1.00Target Price10.00
Avg Volume63.84K52W Range1.26 - 7.74
May-01-24 10:00AM Stock Market Crash Warning: Don't Get Caught Holding These 3 Oil & Gas Stocks (InvestorPlace)
Apr-29-24 04:45PM Recon Technology Receives Nasdaq Delisting Determination; Submits Appeal (PR Newswire) +6.59%
Apr-25-24 04:45PM Recon Technology Announces 1-for-18 Reverse Stock Split (PR Newswire) -5.64%
Mar-11-24 08:30AM Recon Technology Secures US$3 Million in Contracts with Newly Developed Customer for Electronic Components and Materials (PR Newswire)
Mar-04-24 08:30AM Recon Technology to Exhibit Plastic Chemical Recycling Solutions at 2024 Plastics Recycling Conference in Texas (PR Newswire)
Oct-27-23 04:30PM Recon Technology, Ltd Reports Financial Year Results for Fiscal Year 2023 (PR Newswire) -9.84%
08:30AM Recon Receives NASDAQ Minimum Bid Price Requirement Extension (PR Newswire)
Aug-08-23 06:37AM 15 Worst Performing Energy Stocks in 2023 (Insider Monkey)
Jul-18-23 08:30AM Future Gas Station and Jiangsu Jiademan Join Forces to Revolutionize Fueling Services for a Leading Digital Freight Platform (PR Newswire)
Jul-03-23 08:30AM Recon Technology, Ltd Establishes Strategic Partnership with Changxia Digital Energy Technology (Hubei) Co., Ltd., a China Three Gorges Corporation Affiliate (PR Newswire)
BSGM - Biosig Technologies Inc - Stock Price Chart
TickerBSGM [NASD]
CompanyBiosig Technologies Inc
CountryUSA
IndustryMedical Devices
Market Cap19.60MEPS (ttm)-4.05
P/E-EPS this Y81.01%
Forward P/E-EPS next Y-73.33%
PEG-EPS past 5Y20.58%
P/S980.00EPS next 5Y-
P/B-EPS Q/Q51.47%
Dividend-Sales Q/Q-91.11%
Insider Own17.06%Inst Own10.22%
Insider Trans0.00%Inst Trans3.91%
Short Float10.35%Earnings-
Analyst Recom1.00Target Price7.50
Avg Volume1.22M52W Range0.26 - 16.50
Today 12:22PM BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent (GlobeNewswire)
Apr-30-24 02:03PM BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately (GlobeNewswire) +23.88%
07:31AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Apr-04-24 11:35AM BioSig Engages Consulting Firm for Business Model Strategies (GlobeNewswire)
Feb-20-24 10:00AM BioSig Announces Reduction of its Workforce (GlobeNewswire) -15.79%
Feb-06-24 08:30AM BioSig's PURE EP Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases (GlobeNewswire) -21.03%
Jan-31-24 11:15AM BioSig Announces Reverse Stock Split (GlobeNewswire) -10.68%
Jan-30-24 08:30AM BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy (GlobeNewswire) -12.91%
Dec-06-23 02:20PM BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024 (GlobeNewswire)
Nov-13-23 04:30PM BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
ORGN - Origin Materials Inc - Stock Price Chart
TickerORGN [NASD, RUT]
CompanyOrigin Materials Inc
CountryUSA
IndustryChemicals
Market Cap170.00MEPS (ttm)0.16
P/E7.07EPS this Y-17.01%
Forward P/E-EPS next Y18.42%
PEG-EPS past 5Y-
P/S5.90EPS next 5Y-
P/B0.40EPS Q/Q-166.37%
Dividend-Sales Q/Q-
Insider Own15.67%Inst Own23.25%
Insider Trans-0.35%Inst Trans-2.35%
Short Float6.97%EarningsMay 14/a
Analyst Recom2.00Target Price2.98
Avg Volume1.97M52W Range0.44 - 5.04
May-02-24 07:00AM Origin Materials Partners with IMDvista on Worlds First PET Cap and Closure Manufacturing System (Business Wire) +23.66%
May-01-24 04:01PM Origin Materials Announces First Quarter 2024 Earnings Release Date and Conference Call (Business Wire)
Apr-30-24 07:00AM Origin Materials Partners with PackSys Global on Worlds First PET Cap and Closure Manufacturing System (Business Wire) +5.98%
Apr-16-24 11:52AM 14 Cheap Penny Stocks to Buy According to Analysts (Insider Monkey)
Apr-03-24 07:00AM Origin Materials Converts Wood Residue Feedstock into Sustainable Intermediates at Commercial-Scale Plant (Business Wire) +22.22%
Feb-29-24 04:09PM Origin Materials, Inc. Reports Operating and Financial Results for Fourth Quarter and Full Year 2023 (Business Wire)
Feb-15-24 07:00AM Origin Materials Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference Call (Business Wire) +9.57%
Nov-21-23 09:40AM Origin Materials Layoffs 2023: What to Know About the Latest ORGN Job Cuts (InvestorPlace) -9.35%
Nov-20-23 04:12PM Origin Materials Announces Organizational Streamlining to Support Priority Initiatives (Business Wire) -5.78%
Nov-09-23 04:01PM Origin Materials, Inc. Reports Operating and Financial Results for Third Quarter 2023 (Business Wire)
MULN - Mullen Automotive Inc - Stock Price Chart
TickerMULN [NASD]
CompanyMullen Automotive Inc
CountryUSA
IndustryAuto Manufacturers
Market Cap27.45MEPS (ttm)-2356.61
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y44.05%
P/S74.19EPS next 5Y-
P/B0.12EPS Q/Q99.75%
Dividend-Sales Q/Q-
Insider Own1.68%Inst Own11.70%
Insider Trans0.00%Inst Trans-
Short Float20.95%Earnings-
Analyst Recom-Target Price5.17
Avg Volume3.02M52W Range2.36 - 1980.00
May-02-24 09:00AM Pritchard EV and Mobile Road Service Solutions Debut All Electric Mullen ONE Roadside Assistance Vehicle at American Towman Showcase in Las Vegas (GlobeNewswire) -5.70%
May-01-24 09:00AM Mullen Adds One of the Largest US Commercial Dealers, Pritchard EV, to Dealer Network (GlobeNewswire) -21.94%
Apr-30-24 08:13AM Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting (MT Newswires) +9.97%
Apr-29-24 03:51PM Sector Update: Consumer Stocks Rise in Late Afternoon Trading (MT Newswires) +81.01%
03:27PM Sector Update: Consumer (MT Newswires)
02:36PM Top Midday Gainers (MT Newswires)
01:01PM Billionaire Paul Singer Is Betting Big on Sumitomo (SMFG) Stock (InvestorPlace)
12:32PM Bye Bye, Bob Bakish! PARA Stock Pops as Paramount Eyes CEO Ouster. (InvestorPlace)
11:53AM Why Is Mullen Automotive (MULN) Stock Up 27% Today? (InvestorPlace)
09:00AM California Issues HVIP Approval, Granting Mullen's Class 3 EV Trucks a $45,000 Cash Voucher Per Vehicle Sold (GlobeNewswire)
ANVS - Annovis Bio Inc - Stock Price Chart
TickerANVS [NYSE]
CompanyAnnovis Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap56.76MEPS (ttm)-6.22
P/E-EPS this Y55.84%
Forward P/E-EPS next Y9.33%
PEG-EPS past 5Y-126.41%
P/S-EPS next 5Y-
P/B-EPS Q/Q-515.14%
Dividend-Sales Q/Q-
Insider Own26.05%Inst Own11.40%
Insider Trans0.00%Inst Trans-3.09%
Short Float17.85%EarningsApr 04/a
Analyst Recom1.80Target Price33.40
Avg Volume442.35K52W Range5.23 - 22.49
Apr-30-24 10:17AM Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating (MT Newswires) -23.49%
Apr-29-24 02:54PM Top Midday Decliners (MT Newswires) -59.58%
12:12PM Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study (MT Newswires)
10:51AM UPDATE 3-Annovis tumbles as Alzheimer's treatment misses in mid-stage study (Reuters)
10:20AM CORRECTED- Annovis Bio fails to meet main goal of mid-stage Alzheimer's treatment trial (Reuters)
10:10AM Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease (GlobeNewswire)
Apr-24-24 09:55AM Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade (Zacks) +7.24%
Apr-08-24 09:55AM Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High? (Zacks)
Apr-02-24 12:53PM ANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023 (InvestorPlace) -6.52%
07:30AM Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
CNF - CNFinance Holdings Ltd ADR - Stock Price Chart
TickerCNF [NYSE]
CompanyCNFinance Holdings Ltd ADR
CountryChina
IndustryMortgage Finance
Market Cap115.26MEPS (ttm)0.33
P/E5.02EPS this Y63.62%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-31.16%
P/S0.47EPS next 5Y-
P/B0.20EPS Q/Q-33.63%
Dividend-Sales Q/Q-20.81%
Insider Own-Inst Own8.75%
Insider Trans-Inst Trans41.83%
Short Float0.01%EarningsMar 28/b
Analyst Recom1.00Target Price5.00
Avg Volume13.94K52W Range1.53 - 4.10
Apr-26-24 09:26AM CNFinance Files Annual Report on Form 20-F for Fiscal Year 2023 (PR Newswire)
Apr-02-24 10:40AM CNFinance Holdings Limited (NYSE:CNF) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 06:15AM CNFinance Announces Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results (PR Newswire)
Mar-22-24 06:15AM CNFinance to Report Fourth Quarter and Fiscal Year of 2023 Financial Results on Thursday, March 28, 2024 (PR Newswire)
Feb-28-24 03:00PM 7 Penny Stocks to Buy and Hold Forever for Multibagger Gains (InvestorPlace)
Dec-01-23 10:02AM CNFinance Holdings Limited (NYSE:CNF) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-30-23 02:34AM Q3 2023 CNFinance Holdings Ltd Earnings Call (Thomson Reuters StreetEvents)
Nov-29-23 05:45AM CNFinance Announces Third Quarter of 2023 Unaudited Financial Results (PR Newswire)
Nov-23-23 05:00AM CNFinance to Report Third Quarter of 2023 Financial Results on Wednesday, November 29, 2023 (PR Newswire)
Aug-30-23 08:53AM CNFinance Holdings Limited (NYSE:CNF) Q2 2023 Earnings Call Transcript (Insider Monkey)
ABEO - Abeona Therapeutics Inc - Stock Price Chart
TickerABEO [NASD]
CompanyAbeona Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap124.49MEPS (ttm)-2.59
P/E-EPS this Y15.55%
Forward P/E-EPS next Y11.23%
PEG-EPS past 5Y38.92%
P/S35.57EPS next 5Y-
P/B8.14EPS Q/Q-920.75%
Dividend-Sales Q/Q-100.00%
Insider Own5.40%Inst Own52.12%
Insider Trans3.12%Inst Trans22.75%
Short Float7.97%EarningsMar 18/b
Analyst Recom1.00Target Price19.50
Avg Volume593.03K52W Range2.83 - 9.01
Today 11:19AM Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise (MT Newswires) +11.79%
07:30AM Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Apr-23-24 02:04PM Top Midday Decliners (MT Newswires) -53.67%
08:53AM Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today? (InvestorPlace)
07:39AM Top Premarket Decliners (MT Newswires)
07:09AM FDA rejects Abeona cell therapy, asks for more manufacturing data (BioPharma Dive)
Apr-22-24 05:58PM Abeona Therapeutics Shares Slump After Plans to Reapply for Pz-cel Drug Approval (MT Newswires)
04:27PM UPDATE 1-US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:14PM US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:05PM Abeona Therapeutics Provides Regulatory Update on Pz-cel (GlobeNewswire)
CRDF - Cardiff Oncology Inc - Stock Price Chart
TickerCRDF [NASD]
CompanyCardiff Oncology Inc
CountryUSA
IndustryBiotechnology
Market Cap168.56MEPS (ttm)-0.93
P/E-EPS this Y-5.38%
Forward P/E-EPS next Y-8.16%
PEG-EPS past 5Y35.42%
P/S343.99EPS next 5Y-
P/B2.42EPS Q/Q-7.34%
Dividend-Sales Q/Q21.87%
Insider Own8.07%Inst Own12.74%
Insider Trans0.84%Inst Trans-10.89%
Short Float9.70%EarningsMay 02/a
Analyst Recom1.00Target Price10.50
Avg Volume1.92M52W Range0.94 - 6.42
May-02-24 09:54PM CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.91%
05:45PM Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update (GlobeNewswire)
Apr-25-24 04:05PM Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update (GlobeNewswire)
Apr-08-24 04:05PM Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study (GlobeNewswire)
Apr-01-24 08:50AM Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) +7.30%
Mar-21-24 07:55AM Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why (Zacks)
Mar-14-24 08:50AM Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going (Zacks)
08:08AM Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last? (Zacks)
Mar-06-24 04:05PM Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 (GlobeNewswire) +6.58%
NKGN - NKGen Biotech Inc - Stock Price Chart
TickerNKGN [NASD]
CompanyNKGen Biotech Inc
CountryUSA
IndustryBiotechnology
Market Cap31.71MEPS (ttm)-4.10
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-989.64%
Dividend-Sales Q/Q-
Insider Own60.46%Inst Own14.37%
Insider Trans0.01%Inst Trans14.10%
Short Float4.77%Earnings-
Analyst Recom-Target Price-
Avg Volume3.64M52W Range0.78 - 12.88
Apr-29-24 08:00AM NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinsons Disease (GlobeNewswire)
Apr-25-24 04:05PM NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit (GlobeNewswire) +15.79%
Apr-24-24 04:45PM NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.57%
Apr-18-24 04:05PM NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit (GlobeNewswire) -16.50%
Apr-16-24 11:53PM NKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023 (InvestorPlace)
Apr-11-24 08:05AM NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs (GlobeNewswire)
Mar-25-24 04:05PM NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference (GlobeNewswire) -6.90%
Mar-06-24 07:52AM Why Is NKGen Biotech (NKGN) Stock Up 62% Today? (InvestorPlace) +112.30%
Mar-04-24 08:00AM NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conference (GlobeNewswire)
Feb-07-24 08:57AM Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies (News Direct)
XLO - Xilio Therapeutics Inc - Stock Price Chart
TickerXLO [NASD]
CompanyXilio Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap42.82MEPS (ttm)-2.78
P/E-EPS this Y46.94%
Forward P/E-EPS next Y34.58%
PEG-EPS past 5Y-44.91%
P/S-EPS next 5Y-
P/B0.87EPS Q/Q21.81%
Dividend-Sales Q/Q-
Insider Own76.37%Inst Own15.88%
Insider Trans1.73%Inst Trans-4.73%
Short Float4.35%EarningsApr 01/a
Analyst Recom1.50Target Price5.50
Avg Volume1.23M52W Range0.49 - 3.25
Apr-16-24 09:14AM Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why (Zacks)
Apr-01-24 10:53PM XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +41.67%
04:05PM Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-28-24 11:10AM Why Is Xilio Therapeutics (XLO) Stock up 168% Today? (InvestorPlace) +69.01%
07:05AM Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing (GlobeNewswire)
07:00AM Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program (GlobeNewswire)
06:45AM Gilead bets on Xilio cancer drug as biotech restructures (BioPharma Dive)
Feb-28-24 04:01PM Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +5.60%
Jan-31-24 04:01PM Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:30AM Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies (GlobeNewswire)
1⋯678910111213141516⋯20
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.